Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu's Arteritis - ACR Meeting Abstracts

Abstract Number: 1550

Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

SEMA KAYMAZ-TAHRA¹, Salih Ozguven², Nuh Filizoglu², Ali Ugur Unal³, Fatma Alibaz-Oner⁴, Tunc Ones², Tanju Yusuf Erdil² and Haner Direskeneli⁵, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ³Marmara University School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey

Meeting: ACR Convergence 2022

Keywords: Imaging, Nuclear Medicine, Takayasu.s arteritis, Vasculitis

Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Iliofemoral artery disease, which is commonly observed in severe atherosclerosis, may also be present in Takayasu’s arteritis (TAK). In this study we aimed to evaluate the characteristics of TAK patients with or without iliofemoral artery involvement in PET/CT.

Methods: Patients fulfilling ACR 1990 classification criteria for TAK and underwent PET-CT imaging were evaluated retrospectively. Demographic and clinical data were collected from patients’ charts. Traditional cardiovascular risk factors: diabetes, hypertension, hyperlipidaemia, smoking history and body mass index (BMI) were recorded. PET Vascular Activity Score (PETVAS) was used to assess the quantitative PET activity.

Results: Seventy-one PET/CT scans of 52 (F/M: 42/10) patients with TAK were investigated. Mean age was 42.8±14.2 years and mean disease duration 5.6 ±5.3 years. The aortic arch (75%) was the most commonly involved artery. Iliofemoral arteries were involved in 9 (13%) patients. Patients with iliofemoral involvement were older (52.5±17.4 vs 39.9±12.4 years, p=0.036), had lower glucocorticoid (GC) dose (0 (0-7.5) vs 2.5 mg/day (0-80), p=0.049), higher CRP (36.1±28.1 vs 19.7±25.0 mg/L, p=0.041) and higher PETVAS (11.4±9.7 vs 4.2±3.9, p=0.018). Male gender (50% vs 14%, p=0.016) and current smokers (78% vs 35%, p=0.016) were also more present in the iliofemoral involvement group.

Conclusion: Involvement of iliofemoral arteries in PET/CT in TAK patients are associated with atherosclerotic risk factors more frequently. Therefore, anti-atherosclerotic approaches should be implemented more vigorously during the follow-up of TAK patients with lower extremity involvement.

Table 1

Figure 1

Disclosures: S. KAYMAZ-TAHRA, None; S. Ozguven, None; N. Filizoglu, None; A. Unal, None; F. Alibaz-Oner, None; T. Ones, None; T. Erdil, None; H. Direskeneli, None.

To cite this abstract in AMA style:

KAYMAZ-TAHRA S, Ozguven S, Filizoglu N, Unal A, Alibaz-Oner F, Ones T, Erdil T, Direskeneli H. Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/involvement-of-iliofemoral-arteries-in-pet-ct-are-associated-with-atherosclerotic-risk-factors-in-takayasus-arteritis/. Accessed .

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/involvement-of-iliofemoral-arteries-in-pet-ct-are-associated-with-atherosclerotic-risk-factors-in-takayasus-arteritis/

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].